Measuring Concordance Between Point of Care Testing and Central Laboratory Testing in the Fibroscan®-Aspartate Aminotransferase (FAST) Score
Mentor Information
Guy Neff (Department of Hepatology)
Description
The multitude of non-alcoholic steatohepatitis (NASH) clinical trials require diagnostics increasing in invasiveness culminating in liver biopsy have led to endeavors to expedite early serological measurements with point-of-care testing (POCT). As the device moved from the military front lines, the Piccolo Xpress® POCT is a quick user-friendly modality for acquiring accurate, reliable, and reproducible diagnostics for a fraction of the cost of conventional analysis. If the results of Piccolo Xpress are found to be indistinguishable from those produced by high-volume central laboratory testing (CLT), POCT may supplant the current box-and-ship paradigm. Echosens, a specialized ultrasound device to assist with identifying hepatic fat and flexibility has evolved. To assist with this device we examine a composite score combining ultrasound and AST that rapidly and reliably predicts fibrosis stage in NASH patients without the need for biopsy.
Measuring Concordance Between Point of Care Testing and Central Laboratory Testing in the Fibroscan®-Aspartate Aminotransferase (FAST) Score
The multitude of non-alcoholic steatohepatitis (NASH) clinical trials require diagnostics increasing in invasiveness culminating in liver biopsy have led to endeavors to expedite early serological measurements with point-of-care testing (POCT). As the device moved from the military front lines, the Piccolo Xpress® POCT is a quick user-friendly modality for acquiring accurate, reliable, and reproducible diagnostics for a fraction of the cost of conventional analysis. If the results of Piccolo Xpress are found to be indistinguishable from those produced by high-volume central laboratory testing (CLT), POCT may supplant the current box-and-ship paradigm. Echosens, a specialized ultrasound device to assist with identifying hepatic fat and flexibility has evolved. To assist with this device we examine a composite score combining ultrasound and AST that rapidly and reliably predicts fibrosis stage in NASH patients without the need for biopsy.
